Ebola Virus Net is the web resource for anyone interested in ebola. Ebola (Ebola hemorrhagic fever), is a severe, often fatal disease in humans and nonhuman primates such as monkeys, gorillas, and chimpanzees. Ebola is a rare and deadly disease caused by infection with a virus of the family Filoviridae, genus Ebolavirus. There are five identified Ebolavirus species, four of which have caused disease in humans. Ebola is found in several African countries. The first Ebola species was discovered in 1976 near the Ebola River in the Democratic Republic of the Congo. Since then, outbreaks have appeared sporadically in Africa. The largest outbreak to date was the epidemic in West Africa, which occurred from December 2013, to January 2016, with 28,646 cases and 11,323 deaths. Other outbreaks in Africa began in the Democratic Republic of the Congo in May 2017 and 2018. In July 2019, the World Health Organization declared the Congo Ebola outbreak a world health emergency.
When an infection does occur in humans, the virus can be spread to others through direct contact with the blood or body fluids of a person who is sick with Ebola, or through contact with objects that have been contaminated with the blood or body fluids of an infected person. Until recent, no vaccines were effective. In December 2016, Ebola was found to be 70–100% prevented by rVSV-ZEBOV vaccine, making it the first proven vaccine against the disease. More than 100,000 people have been vaccinated against Ebola as of 2019.
The objectives of Ebola Virus Net are to be the public and professional information resource for ebola and to serve as a network in the exchange of information and news related to ebola.
- Outbreak Brief 5: Ebola virus disease (EVD) in the Democratic Republic of Congo – Africa CDC - africacdc.org
Fri, 12 Nov 2021 08:00 GMT
- NMA warns of fresh Lassa fever, Ebola, COVID-19 outbreaks - Guardian
Fri, 03 Dec 2021 03:17 GMT
- Human trials of vaccine for multiple species of Ebola to begin soon - The Guardian
Wed, 10 Nov 2021 08:00 GMT
- UNICEF DRC Ebola Situation Report No.5, 1 to 7 November 2021 - Democratic Republic of the Congo - ReliefWeb
Thu, 11 Nov 2021 08:00 GMT
- UNICEF DRC Ebola Situation Report No.4, 25-31 October 2021 - Democratic Republic of the Congo - ReliefWeb
Sun, 31 Oct 2021 07:00 GMT
- Living with the trauma and stigma of being an Ebola gravedigger in Liberia - Euronews
Thu, 18 Nov 2021 08:00 GMT
- South Sudan - Ministry of Health With Support From WHO Strengthens Ebola Virus Disease Preparedness and Response Readiness in the High-Risk Counties of Morobo and Yei River, Central Equatoria State - AllAfrica.com
Tue, 23 Nov 2021 08:00 GMT
- Sherif Zaki obituary: CDC pathologist dies at 65 – Legacy.com - Legacy.com
Tue, 30 Nov 2021 16:26 GMT
- World Medical Association boss compares new strain of COVID-19 with Ebola - Information-Analytic Agency NEWS.am
Sat, 27 Nov 2021 14:31 GMT
- Flight bans won't stop Omicron - Popular Science
Thu, 02 Dec 2021 18:38 GMT
- You Should Be Afraid of the Next ‘Lab Leak’ - The New York Times
Tue, 23 Nov 2021 08:00 GMT
- Everything we know so far about the Omicron COVID-19 variant - World Economic Forum
Mon, 29 Nov 2021 14:52 GMT
- Death Reported From Ebola-Like Marburg Virus in West Africa - WebMD
Fri, 13 Aug 2021 07:00 GMT
- Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine - Longview News-Journal
Thu, 02 Dec 2021 12:30 GMT
- Ebola virus can lie low and reactivate after years in human survivors - Nature.com
Wed, 15 Sep 2021 07:00 GMT
- PRO/AH/EDR> Ebola update (44): Burkina Faso ex Cote d'Ivoire, 2nd case, NOT
Mon, 30 Aug 2021 11:01:25 -0400
Ebola -- Burkina Faso
On 22 Aug 2021, the Ministry of Health informed the population of the admission to the Medical Emergencies of the Bogodogo University Hospital (CHU-B) of a 22-year-old patient who had stayed in the Republic of [Cote d'Ivoire]. The diagnostic procedure consisted of sampling analysis at the National Reference Laboratory for Viral Haemorrhagic Fever (LNR-FHV at the Muraz Centre) and the Pasteur Institute of Dakar for confirmation. The results obtained make it possible to permanently rule out
- Implications of Glycosaminoglycans on Viral Zoonotic Diseases Mon, 29 Nov 2021 06:00:00 -0500
Zoonotic diseases are infectious diseases that pass from animals to humans. These include diseases caused by viruses, bacteria, fungi, and parasites and can be transmitted through close contact or through an intermediate insect vector. Many of the world's most problematic zoonotic diseases are viral diseases originating from animal spillovers. The Spanish influenza pandemic, Ebola outbreaks in Africa, and the current SARS-CoV-2 pandemic are thought to have started with humans interacting closely...
- Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans Sat, 27 Nov 2021 06:00:00 -0500
Many countries in sub-Saharan Africa have experienced lower COVID-19 caseloads and fewer deaths than countries in other regions worldwide. Under-reporting of cases and a younger population could partly account for these differences, but pre-existing immunity to coronaviruses is another potential factor. Blood samples from Sierra Leonean Lassa fever and Ebola survivors and their contacts collected before the first reported COVID-19 cases were assessed using enzyme-linked immunosorbent assays for...
- Functional Importance of Hydrophobic Patches on the Ebola Virus VP35 IFN-Inhibitory Domain Sat, 27 Nov 2021 06:00:00 -0500
Viral protein 35 (VP35) of Ebola virus (EBOV) is a multifunctional protein that mainly acts as a viral polymerase cofactor and an interferon antagonist. VP35 interacts with the viral nucleoprotein (NP) and double-stranded RNA for viral RNA transcription/replication and inhibition of type I interferon (IFN) production, respectively. The C-terminal portion of VP35, which is termed the IFN-inhibitory domain (IID), is important for both functions. To further identify critical regions in this domain,...
- Natural History of Aerosol-Induced Ebola Virus Disease in Rhesus Macaques Sat, 27 Nov 2021 06:00:00 -0500
Ebola virus disease (EVD) is a serious global health concern because case fatality rates are approximately 50% due to recent widespread outbreaks in Africa. Well-defined nonhuman primate (NHP) models for different routes of Ebola virus exposure are needed to test the efficacy of candidate countermeasures. In this natural history study, four rhesus macaques were challenged via aerosol with a target titer of 1000 plaque-forming units per milliliter of Ebola virus. The course of disease was split...
- Establishing Healthcare Worker Performance and Safety in Providing Critical Care for Patients in a Simulated Ebola Treatment Unit: Non-Randomized Pilot Study Sat, 27 Nov 2021 06:00:00 -0500
Improving the provision of supportive care for patients with Ebola is an important quality improvement initiative. We designed a simulated Ebola Treatment Unit (ETU) to assess performance and safety of healthcare workers (HCWs) performing tasks wearing personal protective equipment (PPE) in hot (35 °C, 60% relative humidity) or thermo-neutral (20 °C, 20% relative humidity) conditions. In this pilot phase to determine the feasibility of study procedures, HCWs in PPE were non-randomly allocated to...
- Tolerance and Persistence of Ebola Virus in Primary Cells from Mops condylurus, a Potential Ebola Virus Reservoir Sat, 27 Nov 2021 06:00:00 -0500
Although there have been documented Ebola virus disease outbreaks for more than 40 years, the natural reservoir host has not been identified. Recent studies provide evidence that the Angolan free-tailed bat (Mops condylurus), an insectivorous microbat, is a possible ebolavirus reservoir. To investigate the potential role of this bat species in the ecology of ebolaviruses, replication, tolerance, and persistence of Ebola virus (EBOV) were investigated in 10 different primary bat cell isolates...
- Nanotechnology Applications of Flavonoids for Viral Diseases Sat, 27 Nov 2021 06:00:00 -0500
Recent years have witnessed the emergence of several viral diseases, including various zoonotic diseases such as the current pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Other viruses, which possess pandemic-causing potential include avian flu, Ebola, dengue, Zika, and Nipah virus, as well as the re-emergence of SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome) coronaviruses. Notably, effective drugs or vaccines against...
- Andrographolide: A Herbal-Chemosynthetic Approach for Enhancing Immunity, Combating Viral Infections, and Its Implication on Human Health Sat, 27 Nov 2021 06:00:00 -0500
Plants consistently synthesize and accumulate medically valuable secondary metabolites which can be isolated and clinically tested under in vitro conditions. An advancement with such important phytochemical production has been recognized and utilized as herbal drugs. Bioactive andrographolide (AGL; C(20)H(30)O(5)) isolated from Andrographis paniculate (AP) (Kalmegh) is a diterpenoid lactones having multifunctional medicinal properties including anti-manic, anti-inflammatory, liver, and lung...
- Human Parainfluenza Virus 3 Phosphoprotein Is a Tetramer and Shares Structural and Interaction Features with Ebola Phosphoprotein VP35 Sat, 27 Nov 2021 06:00:00 -0500
The human parainfluenza virus 3 (HPIV3) poses a risk for pneumonia development in young children and immunocompromised patients. To investigate mechanisms of HPIV3 pathogenesis, we characterized the association state and host protein interactions of HPIV3 phosphoprotein (HPIV3 P), an indispensable viral polymerase cofactor. Sequence analysis and homology modeling predict that HPIV3 P possesses a long, disordered N-terminal tail (P(TAIL)) a coiled-coil multimerization domain (P(MD)), similar to...
- Large-scale infectious disease testing programs have little consideration for equity: findings from a scoping review Thu, 25 Nov 2021 06:00:00 -0500
CONCLUSION: The studies included in our scoping review did not explicitly consider equity in their design or evaluation which is imperative for the success of infectious disease testing programs.